ArticleJournal of cosmetic dermatology2026
Clinical Outcomes of an Innovative Poly-L-Lactic Acid (LASYNPRO) in Facial Rejuvenation: Prospective, Multicenter Spanish Study.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Post-Market Observational Study of Injectable PLLA Microspheres for Facial Rejuvenation.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo evaluate the clinical efficacy, patient satisfaction, safety profile, and biological impact of Poly-L-lactic acid (PLLA LASYNPRO) over 6 months.
methodsThis prospective, multicenter study included patients treated with PLLA-LASYNPRO. The primary end-point was the proportion of participants who achieved a reduction of at least 1 point in the Wrinkle-Severity-Rating-Scale (WSRS). Secondary end-points included the proportion of participants achieving at least a 1-point reduction in the Midface-Volume-Deficit-Scale (MFVDS), the degree of patient satisfaction assessed by the Global-Aesthetic-Improvement-Scale (GAIS), treatment-related biological and structural changes, and the incidence of adverse events (AEs).
resultsThirty-six female subjects were enrolled. Right-side treatment success rates increased from 44.4% at month-1 to 71.9% at month-6 (Cochran's Q, p = 0.005); left-side rates increased from 44.4% to 68.8% (p = 0.006). MFVDS-treated-side success increased significantly (44.4% to 65.6%; p = 0.004). GAIS ratings of "Much Better" or "Better" were reported by 66.7% at month 1 and remained high (65.6% at month-6). Ultrasound and elastography imaging confirmed increased tissue density, reduction of the Sub-Epidermal-Low-Echogenic-Band (SLEB), signs of neocollagenesis, and improved viscoelasticity. Serum P1CP levels rose significantly from 134.6 ± 98.9 ng/mL to a peak of 233.2 ± 163.1 ng/mL at month 2 (p < 0.001 vs. baseline), remaining elevated through month 6 (p = 0.012). AEs were limited to mild-moderate, self-resolving inflammation, erythema, edema, and injection-site discomfort; no serious AEs occurred.
conclusionPLLA-LASYNPRO achieved significant, sustained improvements in facial wrinkles and volume with high patient satisfaction and biological evidence of collagen stimulation. The treatment demonstrates an excellent safety profile. Further large-scale, randomized trials are recommended to confirm long-term efficacy and define its role in aesthetic practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.